Bryostatin-1 and IL-2 Synergize to Induce IFN-γ Expression in Human Peripheral Blood T Cells: Implications for Cancer Immunotherapy1

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Immunology

• Publication date

  2001-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.167.9.4828PMID 11673486
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells.

  2001cited by this paper
• The p38 mitogen-activated protein kinase is required for IL-12-induced IFN-gamma expression.

  2000cited by this paper
• Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.

  2000cited by this paper
• Regulation of T helper type 2 cell immunity by interleukin-4 and interleukin-13.

  2000influential reference
• The p38 Mitogen-Activated Protein Kinase Is Required for IL-12-Induced IFN-γ Expression1

  2000cited by this paper
• A novel transcription factor, T-bet, directs Th1 lineage commitment.

  2000cited by this paper
• IL-4/IL-13 signaling beyond JAK/STAT.

  2000cited by this paper
• A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated human T cells: dependence on CD28 signaling and preferential inhibition of IL-10 production.

  1999cited by this paper
• Enhanced B7-2 Gene Expression by Interferon-γ in Human Monocytic Cells Is Controlled Through Transcriptional and Posttranscriptional Mechanisms

  1999cited by this paper
• Enhanced B7-2 gene expression by interferon-gamma in human monocytic cells is controlled through transcriptional and posttranscriptional mechanisms.

  1999cited by this paper
• The role of IL-13 and its receptor in allergy and inflammatory responses.

  1998cited by this paper
• IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes.

  1998influential reference
• Impaired development of Th2 cells in IL-13-deficient mice.

  1998cited by this paper
• Interferon‐γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway

  1998cited by this paper
• Cutting Edge: IL-12 and IL-18 Differentially Regulate the Transcriptional Activity of the Human IFN-γ Promoter in Primary CD4+ T Lymphocytes

  1998cited by this paper
• Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.

  1998cited by this paper
• CD4+, but not CD8+, T cells from mammary tumor-bearing mice have a down-regulated production of IFN-gamma: role of phosphatidyl serine.

  1998cited by this paper
• Roles of IL-4 and IFN-gamma in stabilizing the T helper cell type 1 and 2 phenotype.

  1997cited by this paper
• T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas.

  1997cited by this paper
• Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role.

  1997cited by this paper
• IL-12 induces T helper 1-directed antitumor response.

  1997cited by this paper
• The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: synergy with interleukin-2 and modulation of interleukin-2Rgamma chain expression.

  1997cited by this paper
• The IFN gamma receptor: a paradigm for cytokine receptor signaling.

  1997cited by this paper
• The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes.

  1997cited by this paper
• Localization and physical mapping of genes encoding the A+U-rich element RNA-binding protein AUF1 to human chromosomes 4 and X.

  1996cited by this paper
• The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.

  1996cited by this paper
• Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

  1996cited by this paper
• The nuclear factor YY1 suppresses the human gamma interferon promoter through two mechanisms: inhibition of AP1 binding and activation of a silencer element

  1996cited by this paper
• The expanding universe of T-cell subsets: Th1, Th2 and more.

  1996cited by this paper
• AUF1 Binding Affinity to A+U-rich Elements Correlates with Rapid mRNA Degradation (*)

  1996cited by this paper
• Negative Transcriptional Regulation of the Interferon-γ Promoter by Glucocorticoids and Dominant Negative Mutants of c-Jun (*)

  1995cited by this paper
• Regulation of interferon‐γ mRNA in a cytolytic T cell clone: Ca2+‐induced transcription followed by mRNA stabilization through activation of protein kinase C or increase in cAMP

  1995cited by this paper
• Cellular and molecular mechanisms of IFN‐γ production induced by IL‐2 and IL‐12 in a human NK cell line

  1995cited by this paper
• Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids

  1995cited by this paper
• Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis

  1995cited by this paper
• Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis.

  1995cited by this paper
• Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2.

  1995cited by this paper
• Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth.

  1995cited by this paper
• SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1

  1995cited by this paper
• Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids.

  1995cited by this paper
• Alterations in NF kappa B/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy.

  1994cited by this paper
• Regulation by interleukin-2 (IL-2) and interferon gamma of IL-2 receptor gamma chain gene expression in human monocytes.

  1994cited by this paper
• Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells.

  1994cited by this paper
• Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro

  1994cited by this paper
• Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.

  1994cited by this paper
• GF109203X, a specific PKC inhibitor, abrogates anti-CD3 antibody-induced upregulation of CD4+ T cell adhesion to B cells.

  1993cited by this paper
• In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.

  1993cited by this paper
• Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor α Induction In Vivo

  1993cited by this paper
• Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines.

  1993cited by this paper
• Bryostatin 1: will the oceans provide a cancer cure?

  1993cited by this paper
• Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.

  1993cited by this paper
• Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.

  1992cited by this paper
• Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2.

  1992cited by this paper
• Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.

  1992cited by this paper
• Bryostatin 1-activated T cells can traffic and mediate tumor regression.

  1992cited by this paper
• Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines.

  1992cited by this paper
• Successful treatment of murine melanoma with bryostatin 1.

  1991cited by this paper
• Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia.

  1991cited by this paper
• The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.

  1991cited by this paper
• Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.

  1990cited by this paper
• Synergistic action of calcium ionophore A23187 and protein kinase C activator bryostatin 1 on human B cell activation and proliferation

  1990cited by this paper
• Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells.

  1989cited by this paper
• Differing modulation of protein kinase C by bryostatin 1 and phorbol esters in JB6 mouse epidermal cells.

  1988cited by this paper
• Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells.

  1988cited by this paper
• Activation of human T lymphocytes by bryostatin.

  1988cited by this paper
• Co-induction of lymphokine synthesis by the antineoplastic bryostatins.

  1987cited by this paper
• Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin.

  1987cited by this paper
• Three activators of protein kinase C, bryostatins, dioleins, and phorbol esters, show differing specificities of action on GH4 pituitary cells.

  1986cited by this paper
• Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor.

  1985cited by this paper
• Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters.

  1985cited by this paper
• Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues.

  1984cited by this paper
• Structure of the human immune interferon gene

  1982cited by this paper
• Isolation and structure of bryostatin 1

  1982cited by this paper

• A novel TOX-nanoluciferase reporter mouse for exploring modulators of T cell exhaustion.

  2025cites this paper
• Bryostatin-1 enhances the proliferation and functionality of exhausted CD8+ T cells by upregulating MAP Kinase 11

  2025cites this paper
• Putative role of natural products as Protein Kinase C modulator in different disease conditions

  2021cites this paper
• Marine Niche: Applications in Pharmaceutical Sciences: Translational Research

  2020cites this paper
• Medicinal Prospects of Marine Flora and Fauna for Drug Discovery

  2020cites this paper
• Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus

  2019cites this paper
• Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4+ T Cells

  2019cites this paper
• Cytotoxic Effect of Crude Extract of Sea Pen Virgularia gustaviana on HeLa and MDA-MB-231 Cancer Cell Lines

  2017cites this paper
• The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function

  2016cites this paper
• The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function

  2016cites this paper
• Antimicrobial , Antioxidant and Cytotoxic Activity of Marine Streptomyces MS-60 Isolated from Bay of Bengal

  2014cites this paper
• The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.

  2012cites this paper
• An Effector Phenotype of CD8+ T Cells at the Junction Epithelium during Clinical Quiescence of Herpes Simplex Virus 2 Infection

  2012cites this paper
• Diversity of marine gliding bacteria in Thailand and their cytotoxicity

  2009cites this paper
• Post-transcriptional control of the interferon system.

  2007cites this paper
• The antineoplastic agent bryostatin-1 differentially regulates IFN-gamma receptor subunits in monocytic cells: transcriptional and posttranscriptional control of IFN-gamma R2.

  2006cites this paper
• Bryostatin-1: pharmacology and therapeutic potential as a CNS drug.

  2006cites this paper
• A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma

  2006cites this paper
• IL-12-Independent Pathways Mechanisms Involving ERK-1 / 2-Dependent Cancer Patients Is Controlled through Dendritic Cells from Normal Donors and and T-bet Expression in Human γ IFN -

  2006cites this paper
• IFN-γ and T-bet Expression in Human Dendritic Cells from Normal Donors and Cancer Patients Is Controlled through Mechanisms Involving ERK-1/2-Dependent and IL-12-Independent Pathways

  2006cites this paper
• The Antineoplastic Agent Bryostatin-1 Differentially Regulates IFN-γ Receptor Subunits in Monocytic Cells: Transcriptional and Posttranscriptional Control of IFN-γR21

  2006cites this paper
• Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma

  2006cites this paper
• Posttranscriptional Control of IFN-Subunits in Monocytic Cells : Transcriptional Receptor γ Differentially Regulates IFN-The Antineoplastic Agent Bryostatin-1

  2006cites this paper
• Identification of a tunable site in bryostatin analogs: C20 Bryologs through late stage diversification.

  2005cites this paper
• Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms

  2005cites this paper
• Enhanced Expression of CD20 in Human

  2005cites this paper
• Interleukin-12 (IL-12) ameliorates the effects of porcine respiratory and reproductive syndrome virus (PRRSV) infection.

  2005cites this paper
• Bryostatin-1 Enhances the Maturation and Antigen-Presenting Ability of Murine and Human Dendritic Cells

  2004cites this paper
• Gene transfer in leukemia and related disorders

  2004cites this paper
• Marine pharmacology in 2001-2: antitumour and cytotoxic compounds.

  2004influential citation
• Effect of IL‐2Rβ‐binding cytokines on costimulatory properties of chronic lymphocytic leukaemia cells: implications for immunotherapy

  2004cites this paper
• Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds.

  2004cites this paper
• Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells

  2004cites this paper
• Effects of conjugated linoleic acid on growth and cytokine expression in Jurkat T cells.

  2003cites this paper
• STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1.

  2003cites this paper
• Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.

  2002cites this paper
• Metastatic melanoma: chemotherapy.

  2002cites this paper
• CHAPTER 12 – BIOSYNTHETIC PRODUCTS FOR ANTICANCER DRUG DESIGN AND TREATMENT: THE BRYOSTATINS

  2002cites this paper
• Primary immune deficiency disease Linking V(D)J recombination and DNA repair: role of artemis in severe combined immune deficiency with abnormal radiosensitivity Related review: V(D)J recombination and DNA repair: lessons from human immune deficiencies

  2002cites this paper
• Post-transcriptional regulation of ura4+ gene expression by glucose in Schizosaccharomyces pombe.

  2002cites this paper